For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
3
views
96
references
 Top references
cited by
8
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      819
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      CX-4945 and siRNA-Mediated Knockdown of CK2 Improves Cisplatin Response in HPV(+) and HPV(−) HNSCC Cell Lines

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Head and neck squamous cell carcinoma (HNSCC) can be categorized into human papillomavirus (HPV) positive or negative disease. Elevated protein kinase CK2 level and activity have been historically observed in HNSCC cells. Previous studies on CK2 in HNSCC did not generally include consideration of HPV(+) and HPV(−) status. Here, we investigated the response of HPV(+) and HPV(−) HNSCC cells to CK2 targeting using CX-4945 or siRNA downregulation combined with cisplatin treatment. HNSCC cell lines were examined for CK2 expression levels and activity and response to CX-4945, with and without cisplatin. CK2 levels and NFκB p65-related activity were high in HPV(+) HNSCC cells relative to HPV(−) HNSCC cells. Treatment with CX-4945 decreased viability and cisplatin IC50 in all cell lines. Targeting of CK2 increased tumor suppressor protein levels for p21 and PDCD4 in most instances. Further study is needed to understand the role of CK2 in HPV(+) and HPV(−) HNSCC and to determine how incorporation of the CK2-targeted inhibitor CX-4945 could improve cisplatin response in HNSCC.

          Related collections

          Most cited references96

          • Record: found
          • Abstract: found
          • Article: not found

          Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

          Ahmedin Jemal, Lindsey A Torre, Rebecca Siegel … (2018)
          This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions. There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018. In both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths), closely followed by female breast cancer (11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) for incidence and colorectal cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%) for mortality. Lung cancer is the most frequent cancer and the leading cause of cancer death among males, followed by prostate and colorectal cancer (for incidence) and liver and stomach cancer (for mortality). Among females, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal and lung cancer (for incidence), and vice versa (for mortality); cervical cancer ranks fourth for both incidence and mortality. The most frequently diagnosed cancer and the leading cause of cancer death, however, substantially vary across countries and within each country depending on the degree of economic development and associated social and life style factors. It is noteworthy that high-quality cancer registry data, the basis for planning and implementing evidence-based cancer control programs, are not available in most low- and middle-income countries. The Global Initiative for Cancer Registry Development is an international partnership that supports better estimation, as well as the collection and use of local data, to prioritize and evaluate national cancer control efforts. CA: A Cancer Journal for Clinicians 2018;0:1-31. © 2018 American Cancer Society.
          Article 0 comments Cited 27703 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods

            J Ferlay, M Colombet, I Soerjomataram … (2018)
            Estimates of the worldwide incidence and mortality from 36 cancers and for all cancers combined for the year 2018 are now available in the GLOBOCAN 2018 database, compiled and disseminated by the International Agency for Research on Cancer (IARC). This paper reviews the sources and methods used in compiling the cancer statistics in 185 countries. The validity of the national estimates depends upon the representativeness of the source information, and to take into account possible sources of bias, uncertainty intervals are now provided for the estimated sex- and site-specific all-ages number of new cancer cases and cancer deaths. We briefly describe the key results globally and by world region. There were an estimated 18.1 million (95% UI: 17.5-18.7 million) new cases of cancer (17 million excluding non-melanoma skin cancer) and 9.6 million (95% UI: 9.3-9.8 million) deaths from cancer (9.5 million excluding non-melanoma skin cancer) worldwide in 2018.
            Article 0 comments Cited 2253 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Head and neck squamous cell carcinoma

              Daniel E. Johnson, Barbara Burtness, C. René Leemans … (2020)
              Most head and neck cancers are derived from the mucosal epithelium in the oral cavity, pharynx and larynx and are known collectively as head and neck squamous cell carcinoma (HNSCC). Oral cavity and larynx cancers are generally associated with tobacco consumption, alcohol abuse or both, whereas pharynx cancers are increasingly attributed to infection with human papillomavirus (HPV), primarily HPV-16. Thus, HNSCC can be separated into HPV-negative or HPV-positive HNSCC. Despite evidence of histological progression from cellular atypia through various degrees of dysplasia, ultimately leading to invasive HNSCC, most patients are diagnosed with late-stage HNSCC without a clinically evident antecedent premalignant lesion. Traditional staging of HNSCC using the tumour-node-metastasis system has been supplemented by the 2017 AJCC/UICC staging system, which incorporated additional information relevant to HPV-positive disease. The treatment approach is generally multimodal, consisting of surgery followed by chemotherapy plus radiation (chemoradiation or CRT) for oral cavity cancers and primary CRT for pharynx and larynx cancers. The EGFR monoclonal antibody cetuximab is generally used in combination with radiation in HPV-negative HNSCC where co-morbidities prevent the use of cytotoxic chemotherapy. The FDA approved the immune checkpoint inhibitors pembrolizumab and nivolumab for treatment of recurrent or metastatic HNSCC and pembrolizumab as primary treatment for unresectable disease. Elucidation of the molecular genetic landscape of HNSCC over the past decade has revealed new opportunities for therapeutic intervention. Ongoing efforts aim to integrate our understanding of HNSCC biology and immunobiology to identify predictive biomarkers that will enable delivery of the most effective, least toxic therapies.
              Article 0 comments Cited 1003 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Veronique Baud: Role: Academic Editor
                Journal
                Journal ID (nlm-ta): Biomedicines
                Journal ID (iso-abbrev): Biomedicines
                Journal ID (publisher-id): biomedicines
                Title: Biomedicines
                Publisher: MDPI
                ISSN (Electronic): 2227-9059
                Publication date (Electronic): 18 May 2021
                Publication date Collection: May 2021
                Volume: 9
                Issue: 5
                Electronic Location Identifier: 571
                Affiliations
                [1 ]Minneapolis VA Health Care System Research Service, Minneapolis, MN 55417, USA; krenx001@ 123456umn.edu (B.T.K.); amy.gravely@ 123456va.gov (A.A.G.); ahmedk@ 123456umn.edu (K.A.)
                [2 ]Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA
                [3 ]Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA; Emiro.Caicedo-Granados@ 123456va.gov (E.C.-G.); mark.klein2@ 123456va.gov (M.A.K.)
                [4 ]Minneapolis VA Health Care System Otolaryngology Section, Minneapolis, MN 55417, USA; bin.x.li@ 123456kp.org
                [5 ]Department of Otolaryngology, University of Minnesota, Minneapolis, MN 55455, USA
                [6 ]Minneapolis VA Health Care System Hematology and Oncology Section, Minneapolis, MN 55455, USA
                [7 ]Department of Medicine, University of Minnesota, One Veterans Drive, Minneapolis, MN 55417, USA
                Author notes
                [* ]Correspondence: trem0005@ 123456umn.edu
                [†]

                Equal contributions by authors.

                [‡]

                Co-senior authors.

                [§]

                Current address: Kaiser Permanente Roseville Medical Center, Department of Head and Neck Surgery, 1600 Eureka Rd, Medical Office Building D, Roseville, CA 95661, USA.

                Author information
                https://orcid.org/0000-0003-3597-2611
                https://orcid.org/0000-0003-4531-6837
                Article
                Publisher ID: biomedicines-09-00571
                DOI: 10.3390/biomedicines9050571
                PMC ID: 8158385
                PubMed ID: 34070147
                SO-VID: 8ac1b715-fb00-46ef-87c0-c25a24d2e4b3
                Copyright © © 2021 by the authors.
                License:

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( https://creativecommons.org/licenses/by/4.0/).

                History
                Date received : 13 April 2021
                Date accepted : 13 May 2021
                Categories
                Subject: Article

                Keywords: head and neck cancer,hnscc,human papillomavirus,hpv,ck2,nfκb,cisplatin,pdcd4,p21
                Data availability:
                Keywords: head and neck cancer, hnscc, human papillomavirus, hpv, ck2, nfκb, cisplatin, pdcd4, p21

                Comments

                Comment on this article

                scite_

                Similar content819

                See all similar

                Cited by8

                See all cited by

                Most referenced authors2,228

                See all reference authors